SCHEMBL4677905

SCHEMBL4677905

O=C(Cc1ccc(S(=O)(=O)c2ccc(F)cc2)[nH]1)C(=O)c1nc[nH]n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.33
AKR1B1 P15121 1/20 0.33
RAB9A P51151 1/20 0.32
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32
MMP9 P14780 1/20 0.32
MMP12 P39900 1/20 0.32
MMP13 P45452 1/20 0.32
MMP14 P50281 1/20 0.32
HTR2A P28223 3/20 0.32
KCNH2 Q12809 3/20 0.32
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.31
HTT P42858 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HTR2C P28335 1/20 0.31
EGFR P00533 2/20 0.31
ERBB2 P04626 2/20 0.31
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674947 0.90 ALDH1A1 (0.36) ALDH1A1MMP1MMP2MMP3MMP9
SCHEMBL4670860 0.89 ALDH1A1 (0.33) ALDH1A1AKR1B1KDM4ELMNAHTT
SCHEMBL4674711 0.82 CXCR3 (0.33) AKR1B1MMP1MMP2MMP3MMP9
SCHEMBL4673364 0.81 SMN1; SMN2 (0.35) ALDH1A1AKR1B1MMP1MMP2MMP3
SCHEMBL4679207 0.80 LMNA (0.36) LMNASMN1; SMN2MAPK1
SCHEMBL4671870 0.80 LMNA (0.34) AKR1B1MMP1MMP2MMP3MMP9
SCHEMBL4677841 0.79 MMP1 (0.33) AKR1B1MMP1MMP2MMP3MMP9
SCHEMBL4680396 0.77 MMP1 (0.39) ALDH1A1AKR1B1MMP1MMP2MMP3
SCHEMBL4677887 0.76 MMP1 (0.36) ALDH1A1AKR1B1MMP1MMP2MMP3
SCHEMBL4671019 0.76 POLB (0.34) ALDH1A1AKR1B1MMP1MMP2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885AKR1B1 17/4885RAB9A 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.